A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Public ClinicalTrials.gov record NCT02702388. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind study being conducted as a postmarketing requirement to the US Food and Drug Administration (FDA) to evaluate whether there is a lower starting dosage of lenvatinib 24 mg once daily (QD) that provides comparable efficacy but has a better safety profile in participants with radioiodine-refractory differentiated thyroid cancer RR-DTC with radiographic evidence of disease progression within the prior 12 months.
Study identification
- NCT ID
- NCT02702388
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2017 (Actual)
- Primary completion
- Dec 12, 2019 (Actual)
- Completion
- Sep 10, 2020 (Actual)
- Last update posted
- Nov 24, 2021
2017 – 2020
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Facility#1 | La Jolla | California | 92093 | — |
| Facility #1 | San Diego | California | 92307 | — |
| Facility #1 | Torrance | California | 90502 | — |
| Facility #1 | Washington D.C. | District of Columbia | 20010 | — |
| Facility #1 | Boston | Massachusetts | 02114 | — |
| Facility #2 | Boston | Massachusetts | 02115 | — |
| Facility #1 | Ann Arbor | Michigan | 48109 | — |
| Facility #1 | Detroit | Michigan | 48201 | — |
| Facility#2 | Morristown | New Jersey | 07962 | — |
| Facility#1 | Summit | New Jersey | 07902 | — |
| Facility #1 | The Bronx | New York | 10461 | — |
| Facility #1 | Columbus | Ohio | 43210 | — |
| Facility #1 | Portland | Oregon | 97239 | — |
| Facility #2 | Philadelphia | Pennsylvania | 19104 | — |
| Facility #1 | Philadelphia | Pennsylvania | 19111 | — |
| Facility #1 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 85 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02702388, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02702388 live on ClinicalTrials.gov.